DWI-ADC值评估乳腺癌新辅助化疗疗效价值的Meta分析

发布时间：2018-05-04 07:29

本文选题：乳腺癌 + 化疗　；参考：《临床放射学杂志》2017年11期

【摘要】：目的探讨用循证医学Meta分析的方法,评估扩散加权成像(DWI)表观扩散系数(ADC)值用于评价乳腺癌新辅助化疗疗效的准确性。方法通过检索Embase、Pubmed、Cochrane图书馆、其他英文数据库及四大中文数据库中的相关文献,搜集符合纳入标准的原始文献进行质量评价、异质性检验、Meta回归分析及亚组分析,并选择相应的效应合并模型进行Meta分析,汇总敏感度(Se)、特异度(Sp)、阳性似然比(+LR)、阴性似然比(-LR)、诊断比值比(DOR)及汇总受试者工作特征曲线(SROC)。结果共纳入13篇英文文献,汇总DWI-ADC值评估乳腺癌新辅助化疗疗效的Se、Sp、+LR、-LR、DOR及SROC曲线下面积(AUC)分别为0.89(0.85~0.92)、0.71(0.66~0.76)、3.12(2.41~4.04)、0.20(0.13~0.29)、21.34(11.36~40.10)、0.88。结论 DWI-ADC值变化率在早期预测乳腺癌新辅助化疗疗效中具有重要意义。
[Abstract]:Objective to evaluate the accuracy of Meta in evaluating the efficacy of neoadjuvant chemotherapy in breast cancer by using the Meta method of evidence-based medicine (EBM) to evaluate the apparent diffusion coefficient of diffusion weighted imaging (DWI). Methods by searching the relevant documents in Embase Pubmedan Cochrane Library, other English databases and four Chinese databases, the quality evaluation of the original documents that met the inclusion criteria, meta regression analysis and subgroup analysis of heterogeneity test were carried out. The results of Meta analysis showed that the sensitivity, specificity, positive likelihood ratio (LRN), negative likelihood ratio (NLR), diagnostic ratio (DOR) and the operating characteristic curve of the subjects were summarized. Results in 13 articles of English literature, DWI-ADC values were collected to evaluate the efficacy of neoadjuvant chemotherapy in breast cancer. The area under the SROC curve and the area under the SROC curve were 0.89, 0.85, 0.92, 0.66, 0.76, 3.12, 2.41, 4.04, 0.20, 0.130.29, 21.3411.36, 40.10, 0.88, respectively. Conclusion the change rate of DWI-ADC is important for early prediction of neoadjuvant chemotherapy in breast cancer.
【作者单位】：南京市江宁医院医学影像科;
【分类号】：R445.2;R737.9

【相似文献】